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Nasopharyngeal carcinoma (NPC) is a malignancy which is consistently associated with the Epstein-Barr
virus (EBV). The structure of the EBV genome in NPC suggests that NPC is a clonal proliferation of epithelial
cells which emerges after EBV infection. The disease develops with high incidence in specific populations in
discrete geographic locations, implicating possible genetic or environmental cofactors. Mutations of the p53
gene are among the most frequent genetic changes found in a large variety of human tumors. Mutations in p53
have been shown to abrogate the suppressor function of wild-type p53 and thus contribute to the transformed
phenotype. To determine if mutation in p53 participates in the development of the malignant clone in NPC, the
structure and sequence of p53 in 42 primary, metastatic, and nude mouse-passaged NPC specimens was
analyzed. A high frequency (6 of 9) of mutations was detected in the nude mouse-passaged tumors, while only
2 of 15 metastatic and 0 of the 18 primary tumors harbored mutant p53. The p53 mutations included
single-point mutations and more extensive changes such as frame shifts, deletion, duplication, or complete loss
of coding sequences. These data indicate that alterations of the p53 gene are unlikely to be involved in the initial
genetic events leading to the clonal outgrowth in NPC. However, although it is a rare NPC which can be
established in nude mice, this growth advantage appears to be conferred on tumors bearing a mutant p53.
Nasopharyngeal carcinoma (NPC), an epithelial malig-
nancy characterized by marked geographic and population
differences in incidence, exemplifies the association of a
human solid tumor with viral infection (11). The Epstein-
Barr virus (EBV), a ubiquitous lymphotrophic herpesvirus,
is consistently detected in NPC, suggesting that EBV infec-
tion is critically involved in the induction of this malignancy
(10, 34).
Structural analyses of the EBV genome have revealed that
the circular intracellular form of the EBV genome can be
distinguished from the linear virion form by identification of
the restriction enzyme fragment representing the fused ter-
mini (33). The terminal restriction enzyme fragments ofEBV
are heterogeneous in size because of various numbers of
copies of the terminal repeat (22, 27). In agarose gel electro-
phoresis, the terminal fragments of the linear genomes
migrate as ladder arrays of fragments. However, in NPC a
single restriction enzyme fragment representing the fused
termini of the EBV genome is detected (33). The clonality of
the viral genomes in NPC suggests, by extension, cellular
clonality. The unique ability to assess cellular clonality in
this epithelial malignancy makes NPC one of the few carci-
nomas which is known to be clonal.
The occurrence of NPC at high incidence in discrete
genetic populations and in specific areas of endemicity
suggests that genetic or environmental cofactors also con-
tribute to the development of NPC. The genetic alterations
that contribute to the emergence of a malignant clone from
the multiple cells which may be infected by EBV are as yet
unknown. Many genes which contribute to malignant pro-
gression have been identified cytogenetically. However,
cytogenetic studies with NPC are limited because of the
difficulties in culturing NPC tissue in vitro (26, 42). Abnor-
mal cellular DNA content, possibly reflecting aneuploidy,
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was detected in 60% of a large number of pretreatment NPC
specimens by using flow cytometry (7). Karyotypic analysis
of two epithelial cell lines established from NPC tissue and
of the rare NPC samples that can be established in nude mice
revealed aneuploidy, but a consistent chromosomal marker
was not identified (26, 46, 47).
Gene abnormalities are believed to underlie the develop-
ment of human cancer. Alterations in oncogenes and sup-
pressor genes in a variety of human cancers have been
documented. The importance of suppressor genes in the
inhibition of tumor growth is becoming increasingly appar-
ent. The wild-type alleles of suppressor genes have regula-
tory functions in cell proliferation and differentiation such
that their loss or inactivation appears to be oncogenic (37).
The human p53 gene is one of the few well-characterized
genes with tumor suppressor function (12, 16, 17). The p53
gene product can be inactivated by virally encoded onco-
genes such as the large T antigen of simian virus 40 and the
E6 gene of human papilloma virus (HPV) (28, 29, 38).
Genetic mechanisms of p53 inactivation include gross alter-
ations such as deletions or rearrangements and, most fre-
quently, more subtle changes such as single-point mutations
(16, 31, 41). Mutations in p53 are among the most frequently
detected genetic alterations in human malignancies and have
been documented in tumors of the colon, breast, lung, brain,
and bladder (2, 31, 40).
NPC is a unique epithelial malignancy in that it develops in
discrete genetic populations and geographic pockets, yet it is
consistently associated with a single, ubiquitous infectious
agent, EBV (10, 11, 34). To date, the role of alterations in
oncogenes and suppressor genes in NPC has not been
determined. In this study, 42 NPC specimens, including two
cell lines established from NPC, were analyzed for alter-
ations of the p53 gene by using restriction enzyme analysis,
differential polymerase chain reaction (DPCR), single-
stranded conformation polymorphism (SSCP) analysis, and
PCR sequencing. The specimens analyzed included primary,
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TABLE 1. Sequences of the oligonucleotides used as PCR and
sequencing primers
Primer Sequencea Fragmentlength
P1 GACGGAATTCGTCCCAAGCAATGGATGAT 2.9 kb
P2 GTCAGTCGACCTTAGTACCTGAAGGGTGA
P3 TTCCTCTTCCTGCAGTACT 209 bp
P4 AGCTGCTCACCATCGCTAT
P5 GGCCTCTGATTCCTCACTGA 170 bp
P6 GCCACTGACAACCACCCTTA
P7 TGTTGTCTCCTAGGTTGGCT 139 bp
P8 CAAGTGGCTCCTGACCTGGA
P9 CCTATCCTGAGTAGTGGTAA 164 bp
PlO TCCTGCTTGCTTACCTCGCT
a The sequence for the p53 primers was taken from the published coding
and intron p53 sequence (4). Primers P1 and P2 contain restriction sites
(EcoRI and SalI).
metastatic, and nude-mouse passaged NPC. While 0 of the
18 primary tumors and only 2 of the 15 metastatic tumors
were found to harbor an altered p53 gene, 6 of 9 nude
mouse-supported tumors contained mutant p53.
MATERIALS AND METHODS
Tissues and cell lines. Primary and metastatic NPC ob-
tained at biopsy were preserved at -70°C. The frozen tissues
were pulverized and dissolved in 4 M guanidine thiocyanate,
and the DNA fractions were extracted twice with phenol and
chloroform after dialysis and proteinase K treatment (35).
The xenografts passaged in nude mice have been previously
characterized and shown to be EBV positive (5, 26, 35). C15
and 2117 were established from primary biopsy material,
whereas C17, C18, and C19 were established from metastatic
tumors. The CNE-1 and CNE-2 epithelial cell lines, which
were established from NPC and can be passaged in nude
mice, became EBV negative during culture (46, 47). Du145,
1LN, and Dupro are cell lines with characterized mutations
in p53 which were established from prostate carcinoma and
can be passaged in nude mice. The HT1080 cell line is a
human fibrosarcoma with unrearranged p53 DNA. The NPC
tumor biopsy specimens were classified histopathologically
as undifferentiated NPC. One specimen, N18, is a WHO 1
squamous cell NPC which is EBV positive (35). All speci-
mens were screened for EBV DNA and were compared with
dilutions of the Raji cell line to determine the EBV genome
copies. The biopsy specimens contained between 5 and 50
copies of EBV, which is similar to the number of EBV
genome copies in the nude mouse-passaged NPC, which
vary between 2 and 30 copies (5). The relative abundance of
EBV DNA suggests that the pieces of biopsy analyzed
biochemically were predominantly tumor tissue.
Total DNA was digested with EcoRI, transferred to nitro-
cellulose, and hybridized to a single-stranded RNA probe
synthesized from a p53 cDNA which was transferred to the
Bluescribe vector (Stratagene, La Jolla, Calif.) (1).
SSCP analysis. The 2.9-kb fragment of genomic DNA,
containing exons 5 to 8 of the p53 gene, was amplified under
standard PCR conditions (30) by using primers P1 and P2
(Table 1). Amplified fragments were recovered from 1%
agarose gels after electrophoresis (Geneclean Kit; Bio 101,
Inc., La Jolla, Calif.). For subsequent SSCP analyses, PCR
was performed with a fraction of the preamplified 2.9-kb
fragment in a reaction containing 200 ,uM (each) dATP,
dGTP, and dTTP; 2 ,uM dCTP; 0.5 ,uM each primer; 50 mM
KCI; 10 mM Tris Cl; 1.5 mM MgCI; 0.001% iwt/vol) gelatin;
0.25 U of Taq polymerase; and 1 ml of [3 P]dCTP (3,000
Ci/mmol, 10 mCi/ml; NEN, Boston, Mass.) in a 10-,u total
volume. By using several different primer pairs (Table 1),
139- to 209-bp fragments within exons 5, 6, 7, and 8 of the
p53 gene were amplified in separate PCRs for 30 cycles at 94,
55, and 72°C. One microliter of the PCR product was
withdrawn and diluted 100-fold in 0.1% sodium dodecyl
sulfate and 10 mM EDTA. Two microliters of this solution
was mixed with 2 RI of formamide containing loading dye,
heated for 5 min at 94°C, and loaded (1.5 ml per lane) onto a
6% nondenaturing polyacrylamide gel. Electrophoresis was
performed at 4°C at 35 W. After being dried, the gel was
exposed to Kodak XAR-film at -80°C for 12 to 48 h by using
an intensifying screen.
PCR sequencing. Five to 10% of the preamplified and
purified 2.9-kb fragments of the p53 gene were subjected to
a second asymmetric PCR reaction with primer pairs P3 and
P4 (exon 5), P5 and P6 (exon 6), P7 and P8 (exon 7), and P9
and P10 (exon 8) (Table 1) (4). The concentrations of the
primers were 0.5 and 0.01 ,uM, respectively, for the first and
second primer of each pair. Both strands were sequenced for
each exon. The respective primers were then used to prime
the sequencing reactions.
The product of the asymmetric PCR was purified and
dissolved in 15 RI of water. An aliquot (7.5 ,ul) was taken for
each sequencing reaction. The commercially available Se-
quenase kit was used for sequencing (United States Bio-
chemical Sequence, Cleveland, Ohio). After electrophoresis
on 8% polyacrylamide-5 M urea gels (2 h at 55 W) and
drying, the gel was exposed to Kodak XAR film overnight.
Differential PCR. Differential PCR was essentially per-
formed as previously described (30). The primer sequences
of the reference genes, beta and gamma interferon, em-
ployed in the differential PCR have been published (18, 30).
Amplification of sequences in exons 5, 7, and 8 of the p53
gene was performed in conjunction with amplification of
single-copy 150- and 170-bp sequences within the beta and
gamma interferon genes, respectively. After electrophoresis
and ethidium bromide staining of the PCR products, the
degree of amplification was determined by densitometric
analysis of the negatives obtained.
RESULTS
Restriction enzyme analysis of p53 in NPC. To determine if
structural alterations in the p53 gene could be detected by
restriction enzyme analysis, total DNA extracted from NPC
specimens was digested with EcoRI and hybridized to a
single-stranded RNA probe synthesized from a p53 cDNA
(Fig. 1) (2). An apparently normal fragment was detected in
three of four NPC tumors recently established in nude mice,
C15, C18, and C19. However, a hybridizable fragment
consistently could not be detected in the C17 tumor, sug-
gesting homozygous deletion of the entire p53 gene. In
primary NPC tumors, the normal 15-kb EcoRI fragment
representing p53 was detected in 40 specimens. These data
indicate that gross rearrangements of the p53 gene are not
prevalent in NPC.
Polymerase chain analysis of p53. To screen the DNA
samples for deletions in p53 which would not be detected by
restriction enzyme analysis, the PCR was employed. A
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FIG. 1. Southern blot analysis of p53 in NPC. Total DNA
extracted from NPC samples was digested with EcoRI and hybrid-
ized to a 32P-labelled single-stranded RNA probe synthesized from a
p53 cDNA. (A) HT1080 (lane 1), Ml (lane 2), C49 (lane 3), C15 (lane
4), C17 (lane 5), C18 (lane 6), C19 (lane 7), N18 (lane 8), 2117 (lane
9), N10 (lane 10), N12 (lane 11), N13 (lane 12), 89-13 (lane 13), and
89-25 (lane 14). (B) HT1080 (lane 1), D5 (lane 2), D6 (lane 3), N3
(lane 4), N57 (lane 5), AlL (lane 6), N31 (lane 7), N62 (lane 8), N57
(lane 9), Pg (lane 10), CIA (lane 11), CL9 (lane 12), CL11 (lane 13),
and Pt (lane 14).
2.9-kb fragment of p53 (primers P1 and P2 [Table 1]) encom-
passing the coding sequences for p53 from exon 4 through 8
was amplified. The ability to successfully amplify this frag-
ment indicates that these coding sequences are intact (Table
2).
In 38 of 40 NPC samples the 2.9-kb fragment of p53 was
successfully amplified (Table 2). In two epithelial cell lines
derived from NPC, CNE-1 and CNE-2, which have been
passaged in nude mice, the 2.9-kb fragment was also suc-
cessfully amplified (46, 47). However, the 2.9-kb fragment
could not be amplified from DNA from the C17 and C19 NPC
tumors, suggesting the presence of deletions.
NPC specimens obtained at biopsy have infiltrating lym-
phocytes and may contain normal tissue. Therefore, to
determine that the hybridization signal and the amplification
of the 2.9-kb fragment represented the tumor tissue, a
modification of PCR, DPCR, was developed to analyze the
NPC specimens for deletions of exons 5, 7, and 8. DPCR has
been successfully used for the detection of allelic loss at the
beta interferon locus in chronic myelogenous leukemia (30).
Amplification of exons 5, 7, and 8 and either beta or gamma
interferon as an internal control is presented in Fig. 2. DNA
prepared from C15 was amplified successfully and shown by
sequence analysis to be normal. This DNA was compared
with that in C17 and C19, in which the initial amplification of
the 2.9-kb fragment had failed. The three exons could be
amplified in C15, whereas in C17 only the reference marker,
gamma interferon, could be detected. In C19, exons 7 and 8
were amplified but exon 5 could not be detected (Fig. 2A).
Amplification of exon 5 or 7 alone compared with amplifica-
tion of beta interferon confirmed deletion of exons 5 and 7 in
C17 and deletion of exon 5 in C19 (Fig. 2B and C). In
contrast, exons 5, 7, and 8 were amplified at equivalent
levels to the interferon reference markers in the NPC spec-
imens indicated in Table 2.
These data indicate the loss of the p53 coding sequences in
C17 and confirm the complete absence of hybridization in
C17 in the Southern blot analyses. In C19, the restriction
enzyme fragment appeared to be slightly smaller than the
15-kb normal fragment. This would result from the deletion
of sequences 5' to exon 5 through the first amplimer, P1.
Detection of p53 mutations by SSCP analysis. Since point
mutation can significantly perturb p53 function, the preva-
lence of p53 mutation was analyzed in the NPC samples.
SSCP analysis (32) was employed to screen DNA samples
for changes in exons 5, 6, 7, and 8 in p53, where mutational
hot spots exist. The basis of this technique is that radiola-
beled PCR products when denatured and allowed to renature
in dilute conditions will assume an intramolecular secondary
structure unique to that sequence. This approach has been
successfully utilized for the detection of point mutations in
the ras gene family and the neurofibromatosis type 1 gene (6,
32).
In this study, SSCP analysis was performed by the ampli-
fication of the individual exons 5, 6, 7, and 8 by using the
2.9-kb PCR fragment as a template. The amplified fragments
representing specific exons were subsequently subjected to
nondenaturing gel electrophoresis. To determine the sensi-
tivity of SSCP for detecting p53 mutations, cell lines estab-
lished from prostate carcinomas with known point mutations
were compared with normal blood and the sample DNAs
from NPC. Abnormal migration patterns and the appearance
of extra bands were consistent and reproducible findings in
the mutant samples with distinctly different banding patterns
when compared with those of the normal control samples.
This analysis of 40 NPC specimens and cell lines revealed
abnormal migration in 6 samples.
SSCP analysis of exon 5 revealed abnormal migration in
the two prostate carcinoma cell lines, 1LN and Dupro,
known to have a deletion of a C residue in codon 138 and
identical abnormal migration in a fresh NPC obtained from a
lymph node metastasis, N18 (Table 2; Fig. 3A). In this
analysis, normal migration was observed in DNA from
normal blood and the C15 tumor. Sequence analysis of exon
5 revealed that N18 had the same deletion of the C residue in
codon 138 without a detectable normal allele (Table 3; Fig.
3B).
Another type of mutation in exon S was detected in C18, a
nude mouse-passaged tumor. As shown in Fig. 4A, normal
migration was detected in DNA from four specimens of
NPC, including metastatic and primary tumors, in compari-
son with an apparent mutation in C18 and the absence of a
normal allele. Sequence analysis of C18 revealed a duplica-
tion of codons 149 to 153 (Table 3; Fig. 4B).
Abnormal migration in both exon 6 and 7 was detected in
a single specimen, NM6, and NPC passaged in nude mice
(35) (Fig. 5 and 6). The abnormal migration for exon 6 in
NM6 and in an NPC metastasis, AlL, is compared with
normal migration in a primary NPC and a posttransplant
lymphoma (Fig. SA). The altered migration in exon 7 in NM6
is compared with normal migration in a second NPC xe-
nograft, NM1, one primary NPC, and three metastatic NPC
(Fig. 6A). Sequence analysis of the NPC, AlL, revealed a
J. VIROL.
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TABLE 2. p53 DNA structure in NPC'
Amplification' of Exon 5 Exon 6 Exon 7 Exon 8
NPC SB 2.9-kb fragment
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a SB, Southern blot; Seq, sequence; N, normal; D, deleted; A, abnormal; I
' +, amplification successful; -, amplification not successful.
nonsense mutation in exon 6 converting a CGA to a termi-
nation codon TGA. The sequence of NM6 indicated multiple
mutations in codons 210 through 215 in exon 6 and a
transition of G for A in codon 234 in exon 7 (Table 3; Fig. SB
and 6B). The SSCP and sequence analysis of exon 6 sug-
gested the absence of a normal allele, whereas in exon 7
NM6 retained a normal allele.
SSCP analysis of exon 8 revealed mutation in DU145, a
prostate carcinoma cell line passaged in nude mice, and in
two cell lines established from NPC, CNE-1 and CNE-2,
also passaged in nude mice (Table 2; Fig. 7). The DU145 cell
line has a point mutation, on one allele, in codon 274 with a
Dupl, duplication; M, mutation.
transversion from G to T, whereas CNE-1 and CNE-2 cell
lines had the identical mutation at codon 280 with a trans-
version from G to C (Table 3; Fig. 6).
Sequence analysis of p53 in NPC. In order to further
confirm the adequate sensitivity of SSCP analysis in the
detection of p53 mutations, DNA from CNE-2 with a p53
mutation in exon 8 was mixed with normal DNA from the
C15 tumor in various proportions from 5 to 50% prior to
amplification. Bands with altered migration representing
CNE-2 were detectable in mixtures in which the CNE-2
DNA represented 5% of the total DNA (data not shown). In
addition, a sampling of NPC specimens which had normal
VOL. 66, 1992









FIG. 2. Deletion analysis by differential PCR. PCR was per-
formed by using amplimers specific for exons 5, 7, and 8 and beta or
gamma interferon as a reference amplification. (A) Amplification
with amplimers for exons 5, 7, 8, and gamma interferon (R). (B)
Amplification with exon 5 and beta interferon. (C) Amplification
with exon 7 and beta interferon. (X174 and HaeIII (lane 1), C15
(lane 2), C17 (lane 3), and C19 (lane 4).
migration detected on SSCP were completely sequenced
through exons 5, 6, 7, and 8 (Table 2). Wild-type sequence
was present in all samples that had been classified as normal
according to the results obtained by SSCP analysis. Se-
quence analysis of mixtures of mutant and normal DNA in
the same sample could detect mutations in the sequencing
reactions with 20% mutant DNA (data not shown).
The sequence analyses of the NPC specimens revealed
that the samples with abnormal banding patterns all con-
tained mutant sequence. Those DNAs with identical migra-
tion by SSCP had identical sequence changes (Fig. 3 and 6).
Furthermore, it was confirmed that SSCP adequately pre-
dicted whether a specimen contained the mutant allele only
or whether both a mutant and a wild-type allele were
present. Samples displaying both the normal and abnormal
banding pattern by SSCP were found to contain the wild type
in addition to the mutant sequence, as in the DU145 cell line
and exon 7 of NM6 (Fig. 5A and B and 6A and C). Although
TABLE 3. p53 mutations in nasopharyngeal carcinoma
NPC Characteristic
C17... Deleted for 2.9 kb
C18... Codon 154 deleted, duplication of codons 149 to 154
C19... Deletion of sequences 5' to exon 5
NM6... Codons 210 to 216, multiple point mutations; codon
234, TAC to TGC (Tyr to Cys)
CNE-1 ... Codon 280, AGA to ACA (Arg to Thr)
CNE-2... Codon 280, AGA to ACA (Arg to Thr)
AlL... Codon 196, CGA to TGA (Arg to termination)
N18... Codon 138, GCC to GC (frame shift deletion)
the PCR can introduce mutations, such mutations are not
detected in the sequence of the total PCR. However, to
eliminate the possibility that DNAs with introduced muta-
tions were preferentially amplified during PCR, the samples
with mutations were sequenced several times from different
amplifications.
Tables 2 and 3 summarize the p53 alterations detected in
NPC. Despite the rarity of p53 mutations in primary NPC
samples, in the nude mouse-passaged NPC tumors, includ-
ing the CNE-1 and CNE-2 NPC cell lines, six of nine
contained mutant p53. The spectrum of mutations included
point mutation, frame shift, deletions, duplications, and
complete loss of coding sequences.
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FIG. 3. Identification of a frameshift deletion in exon 5. (A)
SSCP analysis of exon 5 by using the P3 and P4 amplimers. The
samples include normal blood (lane 1), C15 (lane 2), N18 (lane 3),
1LN (lane 4), Dupro (lane 5), prostate carcinoma (lane 6), and
normal blood (lane 7). (B) Sequence analysis of N18 (M) compared
with DNA from normal blood (N). The arrow indicates the deletion
of a C in codon 138 (GCC).
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FIG. 4. Identification of a duplicated sequence in exon 5. (A)
SSCP analysis of exon 5. Normal blood (lane 1), DU145 (lane 2),
C18 (lane 3), C18 (lane 4), CL9 (lane 5), CL11 (lane 6), Ml (lane 7)
and N12 (lane 8). (B) Sequence analysis of C18 (M) compared with
DNA from normal blood (N). The sequence presented in brackets,
representing codons 149 to 153, is duplicated.
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FIG. 5. Detection of mutation in exon 6. (A) SSCP analysis of
exon 6. Posttransplant lymphoma (lane 1), NM6 (lane 2), AIL (lane
3), and Fle (lane 4). (B) Sequence analysis of AIL (M) detects a
mutation in codon 196 CGA to TGA on one allele compared with
normal sequence (N) in this region in NM6.
DISCUSSION
The data presented demonstrate that although p53 muta-
tions do occur in NPC, the mutations were primarily identi-
fied in the subset of tumors that have been successfully
grown in nude mice. In contrast, in direct clinical specimens
0 of the 18 primary tumors and only 2 obtained from
metastatic NPC were found to harbor p53 mutations. The
absence of p53 mutations suggests that p53 mutation is not a
critical event in the initial transformation of the epithelial
cells. It is unknown, however, when exactly p53 mutations
occur during the neoplastic process. Data obtained from
studies of colon carcinomas suggest that they occur as a late
event in the molecular carcinogenesis (15). In breast carci-
nomas p53 mutations do develop in both primary and meta-
static disease (9). However, the absence of mutation in p53
indicates that the genetic and environmental factors which
contribute to the development of NPC are not manifested in
p53 mutations.
In all the NPC specimens passaged in nude mice with
mutation in p53, there was a loss of the normal allele and
retention of a mutant allele with mutations in two exons in
NM6. The spectrum of mutations, including point mutations,
frame shifts, deletions, and the 15-bp duplication, suggests
that the mutations could have been induced by therapeutic
intervention. The C17 and C19 tumors, which have exten-
sive deletions within p53, had been obtained from patients
whose tumors had recurred after radiotherapy.
It is possible that the ability of NPC to grow in nude mice
identifies those tumors bearing an altered p53 gene. It is
difficult to establish NPC tumors in nude mice, although
heterotransplantation of metastatic tissues is more success-
ful (5, 21). The nude mouse tumors in which p53 mutations
were identified were originally derived from NPC metasta-
ses, and mutations in p53 were only identified in metastatic
NPC specimens obtained at biopsy. Therefore, the detection
of mutant p53 in the specimens passaged in nude mice may
indicate that tumorigenicity in nude mice may selectively
M N
FIG. 6. Identification of mutation in exon 7. (A) SSCP analysis of
exon 7. The specimens presented are NM1 (lane 1), NM6 (lane 2),
N33 (lane 3), CL13 (lane 4), CL4 (lane 5), 89-25 (lane 6), and 107
(lane 7). (B) Sequence of NM6 (M) compared with normal DNA.
The arrow identifies a base pair change (TAC to TGC) on one allele
in codon 234.
identify the rare NPC with mutant p53. It is also possible that
p53 mutation may develop during passage in nude mice. This
would suggest that loss of p53 function in NPC provides a
growth advantage in nude mice but apparently not in vivo.
Interestingly, cervical cancer is a malignancy which is also
associated with viral infection with detection of HPV in the
majority of cervical carcinomas (3, 39). In HPV-associated
cervical cancer, mutations in p53 have not been identified,
presumably because the p53 gene product is inactivated
through the E6 viral gene product (38, 43). In contrast,
mutations in p53 have been detected in HPV-negative cer-
vical cancers (8). These data suggest that p53 may be
involved in cervical carcinoma and can be inactivated either
by somatic mutation in p53 or by interaction with the E6
gene product.
The absence of p53 mutations in most NPC may indicate
interference by EBV infection with some aspect of p53
function. If p53 function is inactivated by an epigenetic
process, selection for cells with a mutation in p53 would not
be necessary. In all NPC in which a single EBV-infected
cellular clone has predominated, the absence of p53 muta-
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FIG. 7. Mutations in exon 8. (A) SSCP ana
specimens presented are CL4 (lane 1), CU145 (
E7 (lane 4), and D6 (lane 5). (B) SSCP of exoi
carcinoma (lane 1), DU145 (lane 2), CNE-1 (lan
C19 (lane 5), C19 (lane 6). (C) Sequence of
codon 274 (G1T to T11T). (D) Sequence ofm
codon 280 (AGA to ACA).
tions suggests such a lack of selection.
grown in nude mice would then reflect a r
of p53 function.
In contrast to NPC, p53 mutation M
significant percentage of both EBV-positi
tive samples of Burkitt's lymphoma, sug
for loss of p53 function in Burkitt's lympi
apparent difference between BL and NPC
differences in the EBV genes which are e3
diseases. It is believed that in Burkitt's 1l
EBV nuclear antigen, EBNA1, is expri
NPC, EBNA1, the latent membrane pr(
encoded by the BamHI A fragment are exj
36, 45). It has been shown that expressi
brane protein 1 suppresses apoptosis o0
death (23). It has also been suggested ti
may be a mediator of apoptosis (44). Per]
latent membrane protein 1 in NPC indirei
p53 function by bypassing its role in med
ACKNOWLEDGMENTS
NPC specimens were obtained from P. Raja
Lanier, C. S. Yang, D. Huang, M. Abdel-Han
Chen, B. X. Ou, and C. L. Chen.
This work was supported by grants CA3297
the National Institutes of Health to N.R.-T.
REFERENCES
1. Baker, S. J., E. R. Fearon, J. M. Nigro, A
Preisinger, J. M. Jessup, D. H. van Tuinen
Barker, Y. Nakamura, R. White, and
Chromosome 17 deletions and p53 gene m
cancer. Science 244:217-221.
2. Baker, S. J., S. Markowitz, E. R. Fearon,
Vogelstein. 1990. Suppression of human (
cell growth by wild-type p53. Science 249
2 3 4 5 6 3. Boshart, M., L. Gissman, H. Ikenberg, A. Kleinheinz, W.Scheurlein, and H. zur Hausen. 1984. A new type of papilloma-
virus DNA, its presence in genital cancer biopsies and in cell
lines derived from cervical cancer. EMBO J. 3:1151-1157.
____ , 4. Buchman, V. L., C. L. Chumakov, N. N. Ninkina, 0. P.
Samarina, and G. P. Georgiev. 1988. A variation in the structure
of the protein coding region of the human p53 gene. Gene
70:245-252.
5. Busson, P., G. Ganem, P. Flores, F. Mugneret, B. Clausse, B.
Caillou, K. Braham, H. Wakasugi, M. Lipinski, and T. Tursz.
1988. Establishment and characterization of three transplant-
A T G C A T G able EBV-containing nasopharyngeal carcinoma. Int. J. Cancer
42:599-606.
6. Cawthon, R. M., R. Weiss, X. U. Gangfeng, D. Viskochil, M.
Culver, J. Stevens, M. Robertson, D. Dunn, R. Gesteland, P.
_ _ O'Connell, and R. White. 1990. A major segment of the neurofi-
bromatosis type 1 gene: cDNA sequence, genomic structure,
and point mutations. Cell 62:193-201.
7. Costello, F., B. R. Mason, R. J. Collins, and J. H. Kearsley.
1990. A clinical and flow cytometric analysis of patients with
nasopharyngeal cancer. Cancer 66:1789-1795.
8. Crook, T., D. Wrede, and K. H. Vousden. 1991. p53 point
mutations in HPV negative human cervical carcinoma cell lines.
M N Oncogene 6:873-875.
9. Davidoff, A. M., B.-J. M. Kerns, J. D. Iglehart, and J. R. Marks.
'aysis of exon 8. The 1991. Maintenance of p53 alterations throughout breast cancer'lane 2), CIU (lane 3), progression. Cancer Res. 51:2605-2610.
8. Primary prostate 10. Desgranges, C., H. Wolf, G. De The, K. Shanmugaratnam, R.
ie 3), CNE-2 (lane 4, Ellouz, N. Cammoun, G. Klein, and H. Zur Hausen. 1975.
nutation in DU145 in Nasopharyngeal carcinoma. X. Presence of Epstein-Barr virus
iutation in CNE-1 in genomes in epithelial cells of tumors from high and medium risk
areas. Int. J. Cancer 16:7-15.
11. de The, G. 1982. Epidemiology of Epstein-Barr virus and
associated diseases in man, p. 25-87. In B. Roizman (ed.), The
The ability to be herpesviruses, vol. 1. Plenum Press, New York.
nore complete loss 12. Eliyahu, D. G., D. Michalovitz, S. Eliyahu, 0. Punhasi-Kimhi,
and M. Oren. 1989. Wild-type p53 can inhibit oncogene-medi-
vas identified in a ated focus formation. Proc. Natl. Acad. Sci. USA 86:8763-8767.
ive and EBV-nega- 13. Fahraeus, R., F. Hu Li, I. Ernberg, J. Finke, M. Rowe, G. Klein,
yesting a selection L. Falk, E. Nilsson, M. Yadav, P. Busson, T. Tursz, and B.gesting a selection Kallin. 1988. Expression of Epstein-Barr virus-encoded proteins
homa (14, 19). This in nasopharyngeal carcinoma. Int. J. Cancer 42:329-338.
may be related to 14. Farrell, P. J., G. J. Allan, F. Shanahan, K. H. Vousden, and T.
pressed in the two Crook. 1991. p53 is frequently mutated in Burkitt's lymphoma
rmphoma, only the cell lines. EMBO J. 10:2879-2888.
essed, whereas in 15. Fearon, E. R., and B. Vogelstein. 1990. A genetic model for
)teins, and a gene colorectal tumorigenesis. Cell 61:759-767.
pressed (13, 20, 25, 16. Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53
ion of latent mem- proto-oncogene can act as a suppressor of transformation. Cell
rprogramed cell 57:1083-1093.program 17. Finlay, C. A., P. W. Hinds, T.-H. Tan, D. Eliyahu, M. Oren, and
hat unmutatedpS3 A. J. Levine. 1988. Activating mutations for transformation by
haps expression of p53 produce a gene product that forms an hsc7o-p53 complex
ctly interferes with with an altered half-life. Mol. Cell. Biol. 8:531-539.
liating apoptosis. 18. Frye, R. A., C. C. Benz, and E. T. Liu. 1989. Detection of
amplified oncogenes by differential polymerase chain reaction.
Oncogene 4:1153-1157.
19. Gaidano, G., P. Ballerini, J. Z. Gong, G. Inghirami, A. Neri, E.
Ldurai, U. Prasad, A. W. Newcomb, I. T. Magrath, D. Knowles, and R. Dalla-Favera.
nid, J. J. Chen, X. J. 1991. p53 mutations in human lymphoid malignancies: associa-
tion with Burkitt lymphoma and chronic lymphocytic leukemia.
79 and CA19014 from Proc. Natl. Acad. Sci. USA 88:5413-5417.
20. Gilligan, K., H. Sato, P. Rajadurai, P. Busson, L. Young, A.
Rickinson, T. Tursz, and N. Raab-Traub. 1990. Novel transcrip-
tion from the Epstein-Barr virus terminal EcoRI fragment,
L. C. Hamilton, J. M. DIJhet, in a nasopharyngeal carcinoma. J. Virol. 64:4948-4956.
l, D. F. Ledbetter, Y. 21. Giovanella, B. C., and J. Fogh. 1985. The nude mouse in cancer
B. Vogelstein. 1989. research. Adv. Cancer Res. 44:69-120.
iutations in colorectal 22. Given, D., D. Yee, K. Griem, and E. Kieff. 1979. DNA of
Epstein-Barr virus. V. Direct repeats at the ends of Epstein-
J. K. Willson, and B. Barr virus DNA. J. Virol. 30:852-862.
colorectal carcinoma 23. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F.
:912-915. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induc-
J. VIROL.
ALTERATIONS OF THE p53 GENE IN NPC 3775
tion of bcl-2 expression by Epstein-Barr virus latent membrane
protein 1 protects infected B cells from programmed cell death.
Cell 65:1107-1115.
24. Hinds, P. W., C. A. Finlay, and A. J. Levine. 1989. Mutation is
required to activate the p53 gene for cooperation with the ras
oncogene and transformation. J. Virol. 63:739-746.
25. Hitt, M. M., M. Aliday, T. Hara, L. Karran, M. D. Jones, P.
Busson, T. Tursz, I. Ernberg, and B. Griffin. 1989. EBV gene
expression in an NPC-related tumour. EMBO J. 8:2639-2651.
26. Huang, D. P., J. H. Ho, W. K. Chan, W. H. Lau, and M. Lui.
1989. Cytogenetics of undifferentiated nasopharyngeal carci-
noma xenografts from Southern Chinese. Int. J. Cancer 43:936-
939.
27. Kintner, C. R., and B. Sugden. 1979. The structure of the
termini of the DNA of Epstein-Barr virus. Cell 17:661-671.
28. Lane, D. P., and L. Crawford. 1979. T antigen is bound to a host
protein in SV40-transformed cells. Nature (London) 278:261-
263.
29. Linzer, D. I. H., and A. J. Levine. 1979. Characterization of a
54,000 MW cellular SV40 tumor antigen present in SV40-
transformed cells and uninfected embryonal carcinoma cells.
Cell 17:43-52.
30. Neubauer, A., B. Neubauer, and E. T. Liu. 1990. Polymerase
chain reaction based assay to detect allelic loss in human DNA:
loss of B-interferon gene in chronic myelogenous leukemia.
Nucleic Acids Res. 18:993-998.
31. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R.
Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P.
Devilee, T. Glover, F. S. Collins, A. Weston, R. Modalli, C. C.
Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur
in diverse human tumour types. Nature (London) 342:705-708.
32. Orita, M., Y. Suzuki, T. Sekiya, and K. Hayashi. 1989. Rapid
and sensitive detection of point mutations and DNA polymor-
phisms using the polymerase chain reaction. Genomics 5:874-
879.
33. Raab-Traub, N., and K. Flynn. 1986. The structure of the
termini of the Epstein-Barr virus as a marker of clonal cellular
proliferation. Cell 47:883-889.
34. Raab-Traub, N., K. Flynn, G. Pearson, A. Huang, P. Levine, A.
Lanier, and J. Pagano. 1987. The differentiated form of nasopha-
ryngeal carcinoma contains Epstein-Barr virus DNA. Int. J.
Cancer 39:25-29.
35. Raab-Traub, N., R. Hood, C. S. Yang, B. Henry, and J. S.
Pagano. 1983. Epstein-Barr virus transcription in nasopharyn-
geal carcinoma. J. Virol. 48:580-590.
36. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J.
Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B
cell growth phenotype reflect novel patterns of Epstein-Barr
virus latent gene expression in Burkitt's lymphoma cells.
EMBO J. 6:2743-2751.
37. Sager, R. 1989. Tumor suppressor genes: the puzzle and the
promise. Science 246:1406-1412.
38. Scheffner, M., B. A. Werness, J. M. Huibregste, A. J. Levine,
and P. Howley. 1990. The E6 oncoprotein encoded by human
papillomavirus types 16 and 18 promotes degradation of p53.
Cell 63:1129-1136.
39. Schwarz, E., U. K. Freese, L. Gissman, W. Mayer, B. Rogen-
buck, A. Stremlau, and H. zur Hausen. 1985. Structure and
transcription of human papillomavirus sequences in cervical
carcinoma cells. Nature (London) 314:111-114.
40. Sidransky, D., A. Von Eschenbach, Y. C. Tsai, P. Jones, I.
Summerhayes, F. Marshall, M. Paul, P. Green, S. R. Hamilton,
P. Frost, and B. Vogelstein. 1991. Identification of p53 gene
mutations in bladder cancers and urine samples. Science 252:
706-709.
41. Takahashi, T., M. M. Nau, I. Chiba, M. J. Birrer, R. K.
Rosenber, M. Vinocour, M. Levitt, H. Pass, A. F. Gazadar, and
J. D. Minna. 1989. p53: a frequent target for genetic abnormal-
ities in lung cancer. Science 246:491-494.
42. Tien, H. F., F. Y. Lee, S. M. Chuang, and C. T. Lin. 1990.
Cytogenetic characterization of a nasopharyngeal carcinoma
cell line and its subline. Cancer Genet. Cytogenet. 49:31-36.
43. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. The E6
proteins encoded by human papillomavirus types 16 and 18 can
complex p53 in vitro. Science 248:76-79.
44. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi,
and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid
leukemic cells that is inhibited by interleukin 6. Nature (Lon-
don) 352:345-347.
45. Young, L., C. Dawson, D. Clark, H. Rupani, P. Busson, T.
Tursz, A. Johnson, and A. Rickinson. 1988. Epstein-Barr virus
gene expression in nasopharyngeal carcinoma. J. Gen. Virol.
69:1051-1065.
46. Zhang, S., Y. Wu, Y. Zeng, L. Zech, and G. Klein. 1982.
Cytogenetic studies on an epithelioid cell line derived from
nasopharyngeal carcinoma. Hereditas 9:723-728.
47. Zhang, S., G. Xiukung, and Y. Zeng. 1983. Cytogenetic studies
on an epithelial cell line derived from poorly differentiated
nasopharyngeal carcinoma. Int. J. Cancer 31:587-590.
VOL. 66, 1992
